Bevacizumab 15 mg/kg

DRUG2 trials

Sponsors

University of Chicago, Hoffmann-La Roche

Conditions

Advanced Liver CancersAdvanced Non-squamous Non-Small Cell Lung Cancer

Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

RecruitingNCT04524871

Hoffmann-La RocheAdvanced Liver Cancers

Start: 2020-11-01End: 2027-12-31Target: 518Updated: 2026-03-27

Unknown Phase

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

CompletedNCT01063283

University of ChicagoAdvanced Non-squamous Non-Small Cell Lung Cancer

Start: 2010-03-31End: 2016-06-30Updated: 2019-11-18

Related Papers

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

2025-01-2141 citations

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Cancer Research Communications2024-03-2914 citations

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer2023-06-0183 citations

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Journal of Clinical Oncology2023-06-0149 citations